MET inhibitors are a class of targeted therapies designed to block the activity of the MET (mesenchymal-epithelial transition) receptor tyrosine kinase. Abnormal activation of the MET pathway is implicated in various types of cancer, promoting tumor growth, angiogenesis, and metastasis. By inhibiting MET signaling, these drugs aim to slow down or stop the progression of cancer.
